StemCells Inc (STEM) Thursday announced that it has completed the enrolment as well as transplantation for the first patient in its Phase I/II clinical trial in dry age-related macular degeneration, or AMD.
The company, engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery, stated that the trial is designed to evaluate the safety and preliminary efficacy of its proprietary HuCNS-SC product candidate as a treatment for dry AMD, and the patient was transplanted with the cells yesterday at the Retina Foundation of the Southwest (RFSW) in Dallas, Texas, one of the leading independent vision research centers in the United States.
"This trial signifies an exciting extension of our on-going clinical research with neural stem cells from disorders of the brain and spinal cord to now include the eye," said Stephen Huhn, MD, FACS, FAAP, Vice President and Head of the CNS Program at StemCells, Inc.
For comments and feedback: editorial@rttnews.com